Viridian Therapeutics, Inc.\DE (VRDN) Other Non-Current Liabilities (2014 - 2026)

Viridian Therapeutics, Inc.\DE's Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $12.5 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 563.48% year-over-year to $12.5 million; the TTM figure through Mar 2026 stood at $12.5 million (up 563.48% YoY), while the FY2025 annual figure was $20.0 million, up 767.85% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $12.5 million, down from $20.0 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $20.0 million in Q4 2025, with the low at $813000.0 in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $1.5 million (2023), against an average of $3.2 million.
• Peak annual rise in Other Non-Current Liabilities reached 3112.12% in 2022, while the deepest fall reached 64.26% in 2022.
• Viridian Therapeutics, Inc.\DE's Other Non-Current Liabilities stood at $1.2 million in 2022, then slipped by 15.61% to $989000.0 in 2023, then soared by 133.37% to $2.3 million in 2024, then surged by 767.85% to $20.0 million in 2025, then slumped by 37.59% to $12.5 million in 2026.
• Business Quant data shows VRDN's Other Non-Current Liabilities at $12.5 million in Q1 2026, $20.0 million in Q4 2025, and $2.6 million in Q3 2025.